Abstract
Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients' care.
Highlights
“Every effort should be made, both from clinicians and pharmaceutical companies, not to limit ” treatment chances for cancer patients and to concomitantly protect their safety
Many countries worldwide are on lockdown to limit the COVID-19 outbreak
Recent studies show that cancer patients present a higher risk of COVID-19 infection and of severe events from COVID-19 [5,6]
Summary
“Every effort should be made, both from clinicians and pharmaceutical companies, not to limit ” treatment chances for cancer patients and to concomitantly protect their safety. One of the contingency measures adopted by most pharmaceutical companies during this emergency is to stop patients’ screening and enrollment in clinical trials [7].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
